Badri, H. http://orcid.org/0000-0002-6134-4347
Satia, I.
Bansal, V.
Mangi, M. A.
Tangaroonsanti, A.
DeVault, K. R.
Lee, A. S.
Houghton, L. A.
Smith, J. A.
Article History
Received: 8 September 2021
Accepted: 30 October 2021
First Online: 19 November 2021
Declarations
:
: JAS has received funding for consultancy and research funds from Afferent Pharmaceuticals, Merck Inc., Bayer, Bellus, GSK, Xention Ltd, Ario Pharma Ltd, Glenmark, Almirall, AstraZeneca, Axalbion, Patara, Verona Pharma, NeRRe Pharmaceuticals, Menlo Pharmaceuticals, and Attenua Inc (outside of submitted work). I.S. reports grants from ERS Respire 3 Marie Curie Fellowship, British Medical Association, and North West Lung Centre Charity, grants and personal fees from Merck Canada, and personal fees from GSK and AstraZeneca, outside the submitted work. HB, VB, MAM, AT, KRD, ASL, and LAH have no conflict of interest.